CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.

3 Penny Stocks Under $1 To Watch After December Fed Meeting

05:30pm, Wednesday, 13'th Dec 2023

The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference. If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize.

Agenus: Getting The Tough Decisions Right With Catalysts Ahead

06:38pm, Friday, 06'th Oct 2023

AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reduction and focus on its most promising pipeline members

Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics

11:25am, Tuesday, 08'th Aug 2023

While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to

2 Low-Priced Stocks That Could Make You Richer

10:15am, Monday, 26'th Jun 2023

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.

Agenus is “turning cold tumors hot and making CTLA-4 cool again”

02:22pm, Tuesday, 06'th Jun 2023

Agenus Inc (NASDAQ:AGEN) and its optimized approach on a validated mechanism (CTLA-4) offer a rare investible opportunity in immuno-oncology (IO), wrote Baird Equity Research analysts in a note publis

Agenus: This Time May Be Different

11:38am, Monday, 05'th Jun 2023

Agenus Inc. has existed for a long three decades, doing nothing much really. They have been producing very strong data from botensilimab lately. Agenus Inc. prospects could now change for the better.

Agenus Announces Virtual Annual Shareholders Meeting

07:30am, Monday, 05'th Jun 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its An

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

10:42am, Tuesday, 09'th May 2023

Agenus (AGEN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.19 per share a year ago.

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

12:55pm, Tuesday, 18'th Apr 2023

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the ne

These 3 Nasdaq Stocks Are on Fire Today: Here's Why

01:55pm, Monday, 17'th Apr 2023

Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficia

Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today

03:53pm, Tuesday, 04'th Apr 2023

Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by